ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2007
Relationship between epidemiologic risk factors and breast cancer recurrence.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 3 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Alcohol consumption and breast cancer prognosis after breast cancer diagnosis: a systematic review and meta‑analysis of the Japanese Breast Cancer Society Clinical Practice Guideline, 2022 edition.Breast cancer (Tokyo, Japan) · 2023Pooled it
- Postdiagnosis body fatness, weight change and breast cancer prognosis: Global Cancer Update Program (CUP global) systematic literature review and meta-analysis.International journal of cancer · 2023Pooled it
- Postdiagnosis dietary factors, supplement use and breast cancer prognosis: Global Cancer Update Programme (CUP Global) systematic literature review and meta-analysis.International journal of cancer · 2023Pooled it
- The impact of cardiovascular risk factors on cancer progression: a prospective study in female breast cancer survivors.Breast cancer research and treatment · 2025Article
- Fear of progression, coping strategies, and associated factors among a sample of Malaysian women with breast cancer.Scientific reports · 2025Article
- Association of hormone replacement therapy and image-detected breast cancer.Frontiers in oncology · 2025Article
- Hormone Replacement Therapy in Cancer Survivors - Review of the Literature.Pathology oncology research : POR · 2020Review
- Prognostic Impact of Menopausal Hormone Therapy in Breast Cancer Differs According to Tumor Characteristics and Treatment.Frontiers in oncology · 2020Article
- Analyzing semi-competing risks data with missing cause of informative terminal event.Statistics in medicine · 2017Article
- Semiparametric model for semi-competing risks data with application to breast cancer study.Lifetime data analysis · 2016Article
- Defining the survival benchmark for breast cancer patients with systemic relapse.Breast cancer : basic and clinical research · 2015Article
- Association between germline single nucleotide polymorphisms in the PI3K-AKT-mTOR pathway, obesity, and breast cancer disease-free survival.Breast cancer research and treatment · 2014Article
- A New Isolated Mediastinal Lymph Node or Small Pulmonary Nodule Arising during Breast Cancer Surveillance Following Curative Surgery: Clinical Factors That Differentiate Malignant from Benign Lesions.Cancer research and treatment · 2014Article
- Loss of LRIG1 locus increases risk of early and late relapse of stage I/II breast cancer.Cancer research · 2014Article
- Genomic copy number imbalances associated with bone and non-bone metastasis of early-stage breast cancer.Breast cancer research and treatment · 2014Article
- Is extracapsular tumour spread a prognostic factor in patients with early breast cancer?International journal of clinical oncology · 2013Article
- Prognostic value of single nucleotide polymorphisms of candidate genes associated with inflammation in early stage breast cancer.Breast cancer research and treatment · 2013Article
- Genetic variants in the vitamin D pathway and breast cancer disease-free survival.Carcinogenesis · 2013Article
- The relationship between eight GWAS-identified single-nucleotide polymorphisms and primary breast cancer outcomes.The oncologist · 2013Article
- Spatial analysis of county-level breast cancer mortality in Texas.Journal of environmental and public health · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
purposeEarly-stage breast cancers are biologically heterogeneous and vary in clinical behavior, supporting the role of factors other than tumor size and lymph node involvement as outcome determinants. We evaluated the effect of epidemiologic breast cancer risk factors on recurrence in women with early-stage disease. PATIENTS AND
methodsMedical records from 2,327 women with early-stage breast cancer, treated at the M.D. Anderson Cancer Center between 1985 and 2000, were used to derive information on epidemiologic, clinical, and histological factors. Cox proportional hazards models were used to estimate the hazard ratios of 5-year risk of breast cancer recurrence adjusted for treatment and stage. Statistical tests were two-sided.
resultsNone of the breast cancer risk factors were associated with recurrence, adjusting for tumor characteristics and treatment. A significant interaction between hormone replacement therapy (HRT) use and tumor hormone receptor status on risk of recurrence (P = .0003) was observed. Among ever-users of HRT, recurrence risk was two-fold lower for estrogen receptor (ER)--positive and progesterone receptor (PR)--positive tumors compared with ER- and PR-negative tumors; whereas, among never-users of HRT, there was no statistically significant association between recurrence risk and receptor status.
conclusionHRT users who develop receptor-positive early-stage disease have better outcomes than those who develop receptor-negative disease. Among never-users of HRT, the expected beneficial effect of ER- or PR-positive tumors on recurrence risk was absent. These data lend support to the notion that the biology of hormone receptor-positive disease in HRT users differs from that in nonusers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.